GxP Validation and Compliance Services for Life Sciences
Life sciences organizations carry a validation burden that compounds when the methodology doesn't match the risk. One Vector applies modern Computer Software Assurance principles to deliver inspection-ready compliance programs that keep pace with AI, cloud, and the iterative update cycles that modern systems demand.
GxP Compliance Consulting Across the Regulated Lifecycle
CSV to CSA Transition and Modernization
Risk-Based Validation That Reduces Overhead Without Reducing Rigor
Legacy Computer System Validation programs apply documentation effort uniformly across systems regardless of patient impact or regulatory risk. The FDA's Computer Software Assurance guidance, finalized in 2025, provides a risk-proportionate framework that concentrates validation effort where it genuinely matters. Organizations that have made the transition report reductions in validation effort of 30 to 70 percent on low-risk systems.
Where we deliver:
Transition from documentation-heavy CSV to risk-based CSA
Rationalization of legacy validation backlog
Validation of SaaS platforms including Veeva, Salesforce, and LIMS
CSA Master Plan development and governance
Outcome
Reduced validation effort on low-risk systems, with focus and rigor maintained on the patient-impacting systems that inspectors scrutinize most closely.
AI and ML Application Validation
GxP Validation Frameworks for Adaptive AI Systems
AI systems evolve after deployment, which means static validation approaches are insufficient. The FDA's 2025 AI guidance and the ISPE GAMP AI Guide both set clear expectations for lifecycle governance, predetermined change control, and continuous drift monitoring. We design validation frameworks that meet those expectations and maintain compliance as models evolve.
Where we deliver:
AI and ML validation frameworks aligned to FDA and EMA expectations
Predetermined Change Control Plans (PCCP)
Model monitoring, drift detection, and human oversight governance
Audit trail architecture and ALCOA++ compliance for AI outputs
Outcome
Validated AI systems that meet current inspection expectations, with a governance structure that keeps them compliant as the model, the regulations, and the business evolve.
Cloud and Software Validation
GxP Compliance for AWS, Azure and SaaS Environments
Cloud deployment shifts responsibility but does not remove it. Organizations that treat cloud validation as equivalent to on-premise validation typically end up with compliance gaps between infrastructure, platform, and application layers. We design validation programs for cloud environments that account for the shared responsibility model and the continuous deployment cycles that modern SaaS platforms operate on.
Where we deliver:
AWS and Azure shared responsibility modelling for GxP environments
GxP-compliant cloud architecture and validated landing zones
Continuous validation frameworks for SaaS releases
Cloud migration validation with full audit lineage
Outcome
Audit-ready cloud environments with compliance coverage across every layer of the architecture.
Data Integrity and ALCOA++
Audit Trail Architecture That Holds Up Under Regulatory Scrutiny
Every system output in a regulated environment is a regulatory record. Data integrity findings are among the most common causes of FDA 483 observations and warning letters, and they are almost always the result of controls that were not embedded in the system architecture from the start. We build ALCOA++ compliant audit trail frameworks into the design of every system we validate.
Where we deliver:
Data lifecycle controls and governance frameworks
Audit trail validation and access control architecture
Data integrity assessments and gap analysis
AI output traceability and digital chain of custody
Outcome
Prevented data integrity findings through architecture rather than remediation, with an audit-ready digital ecosystem across all regulated systems.
Audits and FDA 483 Remediation
Root Cause Resolution That Addresses the System, Not Just the Observation
A 483 observation or warning letter changes the clock and the stakes. Responses that address the surface finding without resolving the underlying system issue tend to generate repeat observations. We conduct root cause analysis, design CAPA programs that address systemic gaps, and prepare organizations for re-inspection with a technically defensible position.
Where we deliver:
Root cause analysis and systemic gap identification
CAPA design, execution, and effectiveness monitoring
Mock inspections and pre-approval inspection preparation
Inspection readiness assessments
Outcome
Fewer repeat findings, stronger long-term quality systems, and a regulatory position that holds up under scrutiny.
Medical Device Quality and QMSR
Preparing for the FDA QMSR Transition and ISO Alignment
The FDA's Quality Management System Regulation, which aligns with ISO 13485, introduced significant changes to quality system requirements for medical device manufacturers. We support QMSR gap assessments, design control updates, and SaMD validation under IEC 62304, ensuring readiness for FDA and global submissions.
Where we deliver:
QMSR gap assessments and remediation roadmaps
Design controls including DHF and DMR
SaMD validation aligned to IEC 62304
ISO 13485 alignment and audit preparation
Outcome
Regulatory readiness for FDA and global submissions, with reduced compliance risk for medical devices and software.
Flexible Staffing and Managed Services Model
Validation Capacity That Scales With Your Program
Validation programs rarely run at a steady pace. System implementations, regulatory milestones, and inspection cycles create surges that lean teams cannot absorb alone. Our flexible managed service model embeds experienced validation professionals directly into your program, available at the pace and duration your situation requires.
Where we deliver:
Embedded validation leads and specialists
Surge support for system implementations and inspection preparation
Fractional quality leadership
eQMS implementation and ongoing validation management
Outcome
Immediate execution capability with a flexible cost structure and faster delivery than a traditional hiring process allows.
Life Sciences Validation Services Built for How Modern Organizations Operate
CSA-First, Not Legacy CSV
We apply risk-proportionate Computer Software Assurance methodology across every engagement, reducing unnecessary effort without compromising the rigor that matters in an audit.
AI-Native Validation Expertise
Most validation firms treat AI validation as a niche add-on. Our team has the regulatory and technical depth to design frameworks for adaptive AI systems in line with current FDA and ISPE guidance.
Cloud and Compliance Integrated
We validate modern cloud architectures and SaaS environments with full compliance coverage across the shared responsibility model, not just legacy on-premise systems.
Execution Throughout
We deliver validation artefacts and demonstrable outcomes, staying engaged through implementation, validation, and audit readiness.
Designed for Lean Teams
Right-sized for small and mid-sized life sciences organizations that need serious GxP compliance capability without the overhead of a large firm.
Built for Leaders Accountable for Compliance Outcomes and Speed
VP and Head of Quality
Inspection readiness without scaling overhead and a methodology that keeps pace with the rate of system change.
Validation Director
Maintaining product quality, regulatory compliance, and operational efficiency ensuring inspection readiness.
CTO and CIO
AI, SaaS, and cloud systems validated correctly the first time, with no rework cycles before audit.
MedTech Product Owner (SaMD)
Navigating the transition to the new FDA QMSR and ISO 13485 standards while maintaining a fast-paced software development lifecycle.
When to engage
- Preparing for an FDA inspection or partner audit
- Scaling post-Series B or entering commercialization
- Modernizing a legacy CSV program
- Deploying AI or cloud systems in GxP workflows
- Responding to 483 observations or warning letters
Frequently asked questions.
01What is the difference between CSV and CSA?
Computer Software Assurance focuses validation effort on high-risk, patient-impacting systems while reducing unnecessary documentation burden for lower-risk systems. The FDA's CSA guidance, finalized in 2025, formalizes this risk-proportionate approach as the current regulatory expectation.
02How much efficiency can a CSA transition realistically deliver?
Most organizations see a 30 to 70 percent reduction in validation effort on low-risk systems when CSA is properly implemented. The efficiency comes from concentrating critical thinking and testing where patient impact is highest.
03How do you validate AI and ML systems in GxP environments?
Through predetermined change control plans, continuous model monitoring, ALCOA++ compliant data integrity controls, and governance structures aligned to the FDA's 2025 AI guidance and the ISPE GAMP AI Guide.
04Can AWS and Azure cloud environments be fully GxP compliant?
Yes, provided the shared responsibility model is clearly defined, validation controls are implemented within the organization's scope, and the platform layer is properly assessed as part of the overall system validation.
05What are the most common causes of FDA 483 observations in validation programs?
Data integrity gaps, incomplete validation coverage, lack of traceability, and failure to follow established procedures are the most frequently cited causes. The majority are systemic rather than isolated incidents.
Where Is Compliance Creating Risk or Friction in Your Organization?
Our team will give you an honest assessment of where your validation program stands, what the gaps are, and the most practical path to inspection readiness.
Explore our other disciplines